{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:12:55Z","timestamp":1783739575624,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejso.2025.111332","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:36:46Z","timestamp":1764808606000},"page":"111332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alteration in estrogen receptor status in metachronous contralateral breast cancer among unilateral early breast cancer patients with BRCA 1\/2 mutations"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7264-3316","authenticated-orcid":false,"given":"Ki Jo","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunhye","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3681-6506","authenticated-orcid":false,"given":"Seung Ho","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Byoel","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Gwe","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1678-3364","authenticated-orcid":false,"given":"Woong Ki","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8915-8944","authenticated-orcid":false,"given":"Dong Seung","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunwoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Jin","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Han","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Joo","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Eon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5405-7385","authenticated-orcid":false,"given":"Jai Min","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.ejso.2025.111332_bib1","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1200\/JCO.2009.24.2495","article-title":"Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2","volume":"28","author":"Malone","year":"2010","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ejso.2025.111332_bib2","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ejso.2025.111332_bib3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"10001","key":"10.1016\/j.ejso.2025.111332_bib4","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","author":"Early Breast Cancer","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejso.2025.111332_bib5","first-page":"422","article-title":"Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer","volume":"37","author":"van de Ven","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejso.2025.111332_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.breast.2021.03.005","article-title":"Association of molecular subtype concordance and survival outcome in synchronous and metachronous bilateral breast cancer","volume":"57","author":"Ding","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.ejso.2025.111332_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fonc.2020.00027","article-title":"Concordance of hormone receptor status and BRCA1\/2 mutation among women with synchronous bilateral breast cancer","volume":"10","author":"Huang","year":"2020","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2025.111332_bib8","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.3390\/diagnostics12123093","article-title":"Allred scoring of ER-IHC stained whole-slide images for hormone receptor status in breast carcinoma","volume":"12","author":"Ahmad Fauzi","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"9","key":"10.1016\/j.ejso.2025.111332_bib9","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1200\/JCO.22.01239","article-title":"Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2","volume":"41","author":"Yadav","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.111332_bib10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41698-024-00559-0","article-title":"Long-term oncologic outcomes of unselected triple-negative breast cancer patients according to BRCA1\/2 mutations","volume":"8","author":"Park","year":"2024","journal-title":"npj Precis Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2025.111332_bib11","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1470-2045(25)00152-4","article-title":"Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study","volume":"26","author":"Blondeaux","year":"2025","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.ejso.2025.111332_bib12","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1200\/JCO-24-01334","article-title":"Clinical behavior of breast cancer in young BRCA carriers and prediagnostic awareness of germline BRCA status","volume":"43","author":"Lambertini","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2025.111332_bib13","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/1078-0432.CCR-03-1061","article-title":"Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type","volume":"10","author":"Foulkes","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.ejso.2025.111332_bib14","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1158\/1078-0432.CCR-04-2424","article-title":"Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype","volume":"11","author":"Lakhani","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejso.2025.111332_bib15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.ejso.2025.111332_bib16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","article-title":"Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study","volume":"19","author":"Copson","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2025.111332_bib17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7150\/ijbs.8579","article-title":"BRCA1 and estrogen\/estrogen receptor in breast cancer: where they interact?","volume":"10","author":"Wang","year":"2014","journal-title":"Int J Biol Sci"},{"issue":"1","key":"10.1016\/j.ejso.2025.111332_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-023-00600-8","article-title":"Estrogen receptor-positive breast cancer and adverse outcome in BRCA2 mutation carriers and young non-carrier patients","volume":"9","author":"Vidarsdottir","year":"2023","journal-title":"npj Breast Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2025.111332_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.onc.1204073","article-title":"Role of direct interaction in BRCA1 inhibition of estrogen receptor activity","volume":"20","author":"Fan","year":"2001","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ejso.2025.111332_bib20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2025.111332_bib21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jamaoncol.2015.0658","article-title":"Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"1","author":"Metcalfe","year":"2015","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2025.111332_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120189","article-title":"Worse breast cancer prognosis of BRCA1\/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis","volume":"10","author":"van den Broek","year":"2015","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.ejso.2025.111332_bib23","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.20.00299","article-title":"Management of hereditary breast cancer: American society of clinical oncology, American society for radiation oncology, and society of surgical oncology guideline","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.111332_bib24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.breast.2021.12.007","article-title":"Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: a nationwide cohort study","volume":"61","author":"Akdeniz","year":"2022","journal-title":"Breast"},{"issue":"6330","key":"10.1016\/j.ejso.2025.111332_bib25","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.ejso.2025.111332_bib26","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1007\/s00432-022-04486-0","article-title":"Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases","volume":"149","author":"L\u00f6b","year":"2023","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325017603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325017603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:28:06Z","timestamp":1783736886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798325017603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0748798325017603"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111332","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alteration in estrogen receptor status in metachronous contralateral breast cancer among unilateral early breast cancer patients with BRCA 1\/2 mutations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111332","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111332"}}